Literature DB >> 28740584

Cardiovascular Disease in Acromegaly.

Morali D Sharma1, Anh V Nguyen1, Spandana Brown1, Richard J Robbins1.   

Abstract

In patients with acromegaly, chronic excess of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) leads to the development of acromegalic cardiomyopathy. Its main features are biventricular hypertrophy, diastolic dysfunction, and in later stages, systolic dysfunction and congestive heart failure. Surgical and/or pharmacological treatment of acromegaly and control of cardiovascular risk factors help reverse some of these pathophysiologic changes and decrease the high risk of cardiovascular complications.

Entities:  

Keywords:  acromegaly; arrhythmia; cardiomyopathy; coronary artery disease; heart failure; hypertension; valvular heart disease

Mesh：

Substances：

Year:  2017        PMID： 28740584      PMCID： PMC5512681          DOI： 10.14797/mdcj-13-2-64

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN： 1947-6108


  31 in total

1.  Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort.

Authors:  Cintia Marques dos Santos Silva; Ilan Gottlieb; Isabela Volschan; Leandro Kasuki; Leila Warszawski; Giovanna Aparecida Balarini Lima; Sergio Salles Xavier; Roberto Coury Pedrosa; Leonardo Vieira Neto; Mônica R Gadelha
Journal:  J Clin Endocrinol Metab       Date:  2015-10-02       Impact factor: 5.958

2.  Acromegaly per se does not increase the risk for coronary artery disease.

Authors:  Hiroyoshi Akutsu; Jürgen Kreutzer; Gerald Wasmeier; Dieter Ropers; Christian Rost; Matthias Möhlig; Henri Wallaschofski; Michael Buchfelder; Christof Schöfl
Journal:  Eur J Endocrinol       Date:  2010-02-09       Impact factor: 6.664

Review 3.  New insights into IGF-1 signaling in the heart.

Authors:  Rodrigo Troncoso; Cristián Ibarra; Jose Miguel Vicencio; Enrique Jaimovich; Sergio Lavandero
Journal:  Trends Endocrinol Metab       Date:  2013-12-28       Impact factor: 12.015

4.  Evidence of an endogenous digitalis-like factor in the plasma of patients with acromegaly.

Authors:  G Deray; M Rieu; M A Devynck; M G Pernollet; P Chanson; J P Luton; P Meyer
Journal:  N Engl J Med       Date:  1987-03-05       Impact factor: 91.245

Review 5.  Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis.

Authors:  Patrick Maison; Anne-Isabelle Tropeano; Isabelle Macquin-Mavier; Andrea Giustina; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2007-02-20       Impact factor: 5.958

Review 6.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

7.  Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.

Authors:  Maria Vittoria Davi'; Luca Dalle Carbonare; Andrea Giustina; Marcello Ferrari; Anna Frigo; Vincenzo Lo Cascio; Giuseppe Francia
Journal:  Eur J Endocrinol       Date:  2008-09-02       Impact factor: 6.664

Review 8.  Acromegalic cardiomyopathy: a review of the literature.

Authors:  M P Matta; P Caron
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 9.  Endocrine aspects of obstructive sleep apnea.

Authors:  Pierre Attal; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

10.  Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study.

Authors:  Emmanuelle Kuhn; Luigi Maione; Amir Bouchachi; Myriam Rozière; Sylvie Salenave; Sylvie Brailly-Tabard; Jacques Young; Peter Kamenicky; Patrick Assayag; Philippe Chanson
Journal:  Eur J Endocrinol       Date:  2015-11       Impact factor: 6.664
View more
  9 in total

Review 1.  IGF-1 and cardiovascular disease.

Authors:  Yusuke Higashi; Sandeep Gautam; Patrick Delafontaine; Sergiy Sukhanov
Journal:  Growth Horm IGF Res       Date:  2019-01-31       Impact factor: 2.372

2.  Insulin signaling in the heart is impaired by growth hormone: a direct and early event.

Authors:  Marina C Muñoz; Verónica G Piazza; Valeria Burghi; Jorge F Giani; Carolina S Martinez; Nadia S Cicconi; Nadia V Muia; Yimin Fang; Sergio Lavandero; Ana I Sotelo; Andrzej Bartke; Patricia A Pennisi; Fernando P Dominici; Johanna G Miquet
Journal:  J Mol Endocrinol       Date:  2022-06-23       Impact factor: 4.869

Review 3.  Fluorescence guided surgery for pituitary adenomas.

Authors:  Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 4.  Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.

Authors:  Matteo Parolin; Francesca Dassie; Chiara Martini; Roberto Mioni; Lucia Russo; Francesco Fallo; Marco Rossato; Roberto Vettor; Pietro Maffei; Claudio Pagano
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 5.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

6.  Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly.

Authors:  Bulent Can; Fatma Olcay Coskun; Sercin Ozkok; Mumtaz Takir
Journal:  Medeni Med J       Date:  2022-06-23

Review 7.  Surgery for acromegaly: Indications and goals.

Authors:  David P Bray; Sai Mannam; Rima S Rindler; Joseph W Quillin; Nelson M Oyesiku
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-04       Impact factor: 6.055

8.  Normalization of plasma growth hormone alleviated malignant ventricular tachycardia in acromegaly.

Authors:  Zhi-Hao Liu; Kang Li; Yan-Sheng Ding; Jian-Xing Qiu; Steven Siyao Meng; Mohetaboer Momin; Sheng-Cong Liu; Tie-Ci Yi; Jian-Ping Li
Journal:  J Geriatr Cardiol       Date:  2018-08       Impact factor: 3.327

9.  Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center.

Authors:  Małgorzata Rolla; Aleksandra Jawiarczyk-Przybyłowska; Jowita Halupczok-Żyła; Marcin Kałużny; Bogumil M Konopka; Izabela Błoniecka; Grzegorz Zieliński; Marek Bolanowski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.